PGR and breast carcinoma: Berstein and colleagues showed that postmenopausal diabetic breast cancer patients treated with metformin as a monotherapy or metformin and sulfonylurea were found to have higher progesterone receptor (PR) tumours than patients treated with other antidiabetic therapies leading to better response of these breast cancer patients to hormone therapy [104].